ABSTRACT
The authors declare a conflict of interest. Xiaoyan Zhang, Yongge Liu and Jeffrey Hafkin are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Kelly Stinson is a consultant providing microbiology services to OPDC. All of the other authors were investigators for the studies described in this paper, and they and/or their institutions received funding support from OPDC to conduct these studies.OPC-167832, an inhibitor of decaprenylphosphoryl-β-